Dear All (Wonkish alert! Get coffee – this is a deep tour into key themes for phage developers!),
At GAMRIC in Lisbon on 24 September 2026, I had a chance to collaborate with 3 experts on the question of how to (finally!) turn a phage-based therapy into a licensed medicine. The core question of this symposium was framed as “how much standardization must phage therapy accept to be dosable, trial-ready, and licensable while preserving the matching to individual bacteria that makes it attractive?”
I gave a brief opening talk that set the scene for talks by Gauri Rao (Univ Southern California) on PK–PD and dose selection, Frenk Smrekar (JAFRAL, a Slovenia-based group) on phage manufacturing, and Radu Botgros (EMA) on regulation.
The top-line take-home message is that phage matching, dose, manufacturing, and regulation have to considered in parallel from the start of the program. A good result in one patient is an encouraging anecdote — but reliably delivering that opportunity to the next patient is the real goal.
This newsletter will offer a tour of symposium; here are the links you’ll need (and while I’m at it, I’ll give a shout-out for GAMRIC 2027 in Bengaluru where we intend to continue our conversations about phage therapy; see the video below of the phage session as a teaser for GAMRIC 2027; see also the meetings calendar for additional details):
- The talks
- (Rex): Opening and program design.
- (Rao): PK–PD and dose.
- (Smrekar): Sustainable manufacturing platform.
- (Botgros): Licensing something built to vary.
- The full symposium recording. Access to this recording is free but you may need an (also free) ESCMID account to view it.
- Key background papers (note especially #3 and #4)
- FDA, 30 Aug – 1 Sep 2021: Workshop entitled “Science and Regulation of Bacteriophage Therapy Workshop.” See the workshop’s landing page for the materials and transcript.
- Pirnay JP et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nature Microbiology. 2024;9:1434–1453. https://doi.org/10.1038/s41564-024-01705-x
- Rao GG et al. Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing. Clinical Pharmacology & Therapeutics. 2025;117:94–105. https://doi.org/10.1002/cpt.3426
- European Medicines Agency. Guideline on quality aspects of phage therapy medicinal products. EMA/CHMP/BWP/1/2024. Draft dated 16 October 2025; consultation 23 October 2025 to 30 April 2026. EMA draft guideline
- [Note: this is the most recent guidance that includes staff at FDA] Moon et al. Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance. Nat Commun 16, 10883 (2025). https://doi.org/10.1038/s41467-025-64608-3
- Würstle S, Lieberknecht-Jouy SC, Düchting A, et al. A consensus-based guideline for personalized bacteriophage therapy. Nature Medicine. 2026;32:3578–3594. Published online 21 September 2026. https://doi.org/10.1038/s41591-026-04654-6
- Related AMR.Solutions newsletters
- 23 Oct 2024: “NIAID RFA: Centers for Accelerating Phage Therapy (CAPT-CEP)”
- 6 Jun 2025: “MHRA compilation of regulatory guidance on phage products”
- 8 Dec 2025: “Phage therapy: Regulatory perspectives from TATFAR”
- 11 Dec 2025: “Phage therapy: Further notes related to the recent TATFAR paper”
- 3 Jul 2026: “WHO Webinars: Pediatric antibiotic R&D and Bacteriophage Community of Practice”
The speakers have kindly agreed to share their decks. Use this newsletter as a guide to their key points. Let me also confess here that I’ve been experimenting with using an AI agent (ChatGPT in my case) to construct outlines and double-check references. So (full disclosure), some of this text was written by ChatGPT. I’ve learned that the key is to very carefully construct and limit your request – and then check everything for accuracy. It’s really an idiot savant, but a fascinating one. With my disclaimer stated, we’re off to a tour of the symposium!
1: The four Rs of phage development (Rex)
The right phage for the right patient. In my opening talk, I emphasized that phage specificity shapes the entire development program. A phage that kills one strain may leave another strain of the same species untouched. Coverage therefore needs a deliberate strategy: a fixed cocktail, a characterized bank from which phages can be selected, or a preparation tailored to an individual patient. Each model makes different demands on diagnostics, supply, and the evidence needed to support its use [slides 4–7].
The right dose, reproducibly. These complete the four Rs. The program must connect the patient’s isolate to active phage, a suitable regimen, and a dependable supply. If composition, activity, or host range changes, we need to understand what that change means for the medicine being administered. Reproducibility is the common thread through all four talks [slides 6 and 10–12].
Encouraging cases create a development question but do not create an approvable medicine. Pirnay et al.’s retrospective series of 100 consecutive cases reported clinical improvement in 88/114 targeted infections (77.2%) and bacterial eradication in 65/106 infections with microbiological follow-up (61.3%). These are infection-level results, and many treatments included antibiotics. They support further development, but the uncontrolled design cannot establish how much benefit phage added. Matching, delivered dose, and product consistency offer important explanations to investigate when case-series experience and randomized studies diverge [slide 8].
2: Dose and exposure at the infection site (Rao)
A replicating agent makes exposure a moving target. Phage concentrations reflect both removal by the body and amplification in susceptible bacteria. The bacterial population is simultaneously the target and the means of producing more phage. Whether amplification occurs depends on the phage–bacterium pairing and conditions at the infection site. Conventional PK–PD concepts remain useful, but they need to accommodate these coupled dynamics [slides 2–6].
A laboratory ratio cannot prescribe a clinical regimen. Multiplicity of infection (MOI), the ratio of phage to bacteria in an experiment, is difficult to translate into a dose when the patient’s bacterial burden is uncertain and changing. We need to know whether infectious phage reaches the target in sufficient quantity and remains active there. Route, timing, and repeat dosing matter. Susceptibility testing also needs to characterize more than a simple yes/no interaction [slides 7–10 and 14].
The dose intended must be the dose delivered. PhagoBurn is an instructive example: patients received substantially less active phage than intended after the preparation lost titre, and bacterial burden fell more slowly than with standard care. This makes potency and stability part of interpreting a clinical result. Gauri also emphasized testing phage–antibiotic combinations: interactions and treatment sequence can help or hinder activity. The appropriate regimen has to be demonstrated for the combination being developed [slides 10–14].
3: Manufacturing: What are the release specifications for a phage product?
Phages are propagated in bacteria! So, manufacturing has to manage both the phage and the bacterial host. Host selection and characterization influence yield, variability, and the impurities that must subsequently be removed. A sequenced, curated phage bank, supported by suitable bacterial banks, gives the program an identity and starting material it can return to [slides 4–7].
Purification must preserve the medicine (the phage). Removing bacterial materials (endotoxin, host DNA, and proteins) while retaining infectious phage is a practical balancing act. Endotoxin is particularly important for intravenous use. Release specifications must address identity, biological activity, and purity, with stability data that support storage and use. A high starting titre does not solve those problems by itself [slides 5 and 8–9].
Some biological variation will remain — how do we set the limits on variability? The manufacturing task is to define what can vary and show that the process repeatedly delivers material within appropriate specifications. A platform built on characterized banks, validated processes, and comparability could make adding or swapping phage more manageable. That is a technical foundation for regulatory discussion, rather than an already available platform licence. Turnaround and logistics also matter if the patient needs a matched preparation quickly [slides 10–13].
3.5: (pause to reflect) Where are we in our thinking?
With those 3 talks complete, we can use this slide from Radu’s talk as way to integrate the perspectives:
- Program design: The unit of development is the program, not the molecule (or phage)
- PK-PD and dose: Antibiotic-style exposure curves won’t work here! Dose is a tricky concept!
- Manufacturing: Consistency means variation within justified limits, not identical batches
That slide brings us neatly to the final talk. Once we can describe and control the variation, how do we build an authorization around it?
4: Access and a route to authorization (Botgros)
The development route must fit the intended product. Radu’s central comparison is shown below. A fixed cocktail is easier to define within a conventional marketing-authorization dossier. Personalization introduces a harder question: what evidence and controls would support preparations whose composition changes with the patient? Quality, safety, and efficacy still have to be addressed [slides 4–7].
Access and authorization answer different questions. Radu described pharmacy preparation for individual patients, including the Belgian magistral model, as a way to enable personalized treatment. Such access can produce valuable experience, but it does not by itself establish the comparative benefit–risk evidence needed for broad authorization. His platform/bank model is a proposed direction: a common quality system, supported by comparability and change control, could connect defined preparations to a wider characterized library. It was explicitly presented as an approach still to be developed [slides 7–10].
A concrete control strategy is the basis of the emerging development framework. EMA’s October 2025 draft addresses manufacture and quality control; its consultation closed on 30 April 2026. It does not supply a complete clinical development pathway for personalized products. His practical message was to seek early, repeated advice on the intended product, matching test, and control strategy [slides 6 and 11–12]. Useful companion reading is found in the recent consensus guideline on personalized phage therapy (Nature Medicine 2026, links above).
Wrapping up
Where does that leave us? We started with the core question of “how much standardization must phage therapy accept to be dosable, trial-ready, and licensable while preserving the matching to individual bacteria that makes it attractive?” After these talks, we can see a coherent path: connect the matching test, the regimen, and the manufacturing controls to the benefit we want to demonstrate.
And at least from an EMA perspective (but I think also relevant to FDA based on publications to date – see reference list at top of this newsletter), here’s a great closing slide (Botgros, slide 11) with the key message: “Do not wait for perfect guidance! Engage early with your control strategy in hand!”
Many thanks to Gauri, Frenk, and Radu for illuminating the path forward. Read the decks, watch the discussion, and keep the four Rs in mind!
All best wishes, –jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.
John’s Top Recurring Meetings
Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking. IDWeek (October) and ECCMID (April) are much larger meetings but also provide opportunities for networking with a substantial, focused audience via their Pipeline sessions. Hope to see you there!
- 23-24 Mar 2027 (Basel, Switzerland): The 10th AMR Conference (3-4 Mar 2026) is now over and offered a rich program that included a 10-year retrospective (we’ve done a lot!), regulatory updates, discussions of how to pursue development in China, and much more … in addition to being a superb opportunity for networking! The program for the 2027 conference is now live; abstract submissions begin Nov 2026 and close January 15, 2027.
- 9-13 April 2027 (Stockholm, Sweden): ESCMID Global 2027, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. Details won’t be out for some months, but the website is here. I do know that the meeting schedule will again include a Science Policy Forum on Friday 9 April 2027 (see here the newsletter about the 2026 science policy forum) and all who are interested in Pull incentives and the antibiotic ecosystem should plan to be there!)..
- 7-9 Sep 2027 (Bengaluru [Bangalore], India): The 3nd GAMRIC, the Global AMR Innovators Conference. Formerly the ESCMID-ASM (or ASM-ESCMID depending on location) Joint Conference on Drug Development for AMR, 2027 will be the 12th year for this series that is now under the joint sponsorship of CARB-X, ESCMID, LifeArc,GARDP, BEAM Alliance, Boston University, and AMR.Solutions. The 2026 meeting in Lisbon was superb and included substantial networking time (drinks on the lawn!), a keynote lecture by Karen Bush on the threat to beta-lactams due to the emergence of PBP3 mutations and sessions on program design for phage, development for pediatrics, and more! Check out the 2.5-minute YouTube video summary — and you can expect similar quality in 2027 in Bengaluru! Mark your calendar — details will follow in the spring of 2027.
- 6-9 Oct 2027 (Boston, MA, USA): IDWeek 2026, the annual meeting of the Infectious Diseases Society of America, has just closed. As always, the program provided a substantial opportunity to present a product to a large audience (see also adjacent note about ESCMID) as well as opportunities to present at an IDWeek Pipeline Session. Details will follow in due course about IDWeek 2027.
Upcoming meetings of interest to the AMR community:
- 18-24 Nov 2026 (everywhere, but not quite all at once): World AMR Awareness Week is happening! Here are some links to active partners: WHO, US CDC, UK Government; I’m sure I’ve not found them all!
- 23 Nov 2026 (virtual, 1-2.30p CET): WHO will host a webinar entitled: “TrACSS at 10 years: Tracking Global Progress on Antimicrobial Resistance.” TrACSS (Tracking AMR Country Self-Assessment Survey) has now being running for 10 years (!!) and this webinar will discuss its progress. Go here to register.
- [NEW] 26 Nov 2026 (virtual, 10-11.30a CET): South Centre and WHO are hosting a webinar on the new WHO guidance entitled: “Integration of equity into national action plans on antimicrobial resistance: guidance to complement the people-centred approach.” Go here to register.
- 27-29 Jan 2027 (Las Vegas, USA): IMARI (Interdisciplinary Meeting on Antimicrobial Resistance and Innovation) sponsored by IDSA and ASM. Abstract submissions are open through 19 Aug; registration and housing will open later this summer.
- 4 Feb 2027 (in person, Liverpool, UK): Bionow‘s Bioinfect 2027 Conference on AMR. Good networking! Go here for details and to register.
- 9-11 Feb 2027 (virtual, 1-5p GMT each day): ACC2027 (Antimicrobial Chemotherapy Conference 2027), sponsored by GARDP and BSAC (British Society for Antimicrobial Chemotherapy) in collaboration with EUP OHAMR (European Partnership on One Health Antimicrobial Resistance). This 3-day online conference includes both symposia and poster presentations. Go here for details and to register. Note that the abstract submission deadline is 16 Nov 2026.
- 23-24 Mar 2027 (Basel, Switzerland): The 11th AMR Conference sponsored by the BEAM Alliance. See list of Top Recurring meetings, above.
- 9-13 April 2027 (Stockholm, Sweden): ESCMID Global 2026, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. See Recurring Meetings list, above.
- [NEW] 15 Jun 2027 (Toulouse, France; in person): Prof. Kevin Outterson (Boston University) and the Toulouse School of Economics (TSE) are collaborating to host a 1-day symposium entitled “The Economics of Antimicrobial Resistance: Innovation, Access, and Stewardship.” Per Kevin, “…, we are bringing together researchers working across the economics of AMR and antibiotic innovation, including stewardship and prescribing, diagnostics, R&D incentives, market failures, pricing and procurement, and new policy approaches to stimulate antimicrobial innovation.” Submission of papers for the meeting is invited; the due date for submissions is 16 Jan 2027. Note that the 15 Jun symposium would be followed by TSE’s annual 2-day Health Economics symposium. Also note that the program committee for both events includes Jean Tirole, winner of the Nobel Prize in Economics in 2014. Go here for the webpage for the AMR symposium and here for the webpage for all of TSE’s symposia.
- 27 Jun – 1 Jul 2027 (Ascona, Switzerland): NCCR-AntiResist will host the 3rd edition of its multi-day conference on antibiotic R&D. This biennial meeting has a similar structure to a Gordon Research Conference and its timing has been adjusted to be 1-year off-sync with the actual GRC (next edition of which is March 2028 — see below). Attendance requires an application; details on how to do this as well as the preliminary program are now available at the conference website.
- 7-9 Sep 2027 (Bangalore, India): GAMRIC the Global AMR Innovators Conference. See list of Top Recurring meetings, above..
- 6-9 Oct 2027 (Boston, MA, USA): IDWeek 2027. See list of Top Recurring meetings, above.
- 16-24 Oct 2027 (Annecy, France, residential in-person program): ICARe (Interdisciplinary Course on Antibiotics and Resistance). This will be year 11 for this course. Patrice Courvalin orchestrates content with the support of an all-star scientific committee and faculty. The resulting soup-to-nuts training covers all aspects of antimicrobials, is very intense, and routinely gets rave reviews! Registration will open during the spring of 2027, so for now just mark your calendar with the dates and keep an eye on the course website for updates.
- [Placeholder] ??? Mar 2028 (yes, that’s 2028, with location TBD): The 2028 Gordon Research Conference (GRC, https://www.grc.org/) entitled “Antibacterials of Tomorrow to Combat the Global Threat of Antimicrobial Resistance” and its related Gordon Research Seminar (GRS) for young doctoral and post-doctoral researchers will be sometime in March 2028. The organizers hope to coordinate dates and location with the 2028 BEAM-AMR meeting. Details to follow — mark your calendar!
Self-paced courses, online training materials, and other reference materials:
- The COMBINE Pneumonia Model is a standardized murine lung infection model designed for preclinical evaluation of novel small-molecule antibiotics. The model combines a consensus lung infection protocol with a repository of well-characterized, strains of Klebsiella pneumoniae and Pseudomonas aeruginosa that are available through the DSMZ (IMI COMBINE Preclinical Bacterial Strain Repository). Developed by the Innovative Medicines Initiative COMBINE project, the model provides a framework for antibiotic efficacy studies and helps provide consistency across preclinical research.
- OpenWHO: “Antimicrobial Resistance in the environment: key concepts and interventions.” Per the webpage for the course, it will teach you “…why addressing AMR in the environment is essential and gain insights into how action can be taken to prevent and control AMR in the environment at the national level.” This course builds on WHO’s 2024 Guidance on wastewater and solid waste management for manufacturing of antibiotics. For further reading, see also the 25 Sep 2023 newsletter entitled “Manufacturing underpins both access and stewardship: Cefiderocol as a case study” and the 28 Jan 2024 newsletter entitled “EMA Concept Paper: Guidance on manufacturing of phage products”.
- GARDP’s REVIVE website provides an encyclopedia covering a range of R&D terms, recordings of prior GARDP webinars, a variety of viewpoint articles, and more! Check it out!
- GARDP’s https://antibioticdb.com/ is an open-access database of antibacterial agents.
- The CARB-X website provides a range of recordings from its webinars, bootcamps, and more. A bit of browsing would be time well spent!
- British Society for Antimicrobial Chemotherapy offers an eLearning section: Education – The British Society for Antimicrobial Chemotherapy.
- CARB-X have announced their second 2026 funding round. The 4 funding themes are as below. The application window runs 10-23 Nov 2026; see the 2 Sep 2026 newsletter for more details:.
- Direct-acting therapeutics for infections caused by Gram-negative bacteria
- Novel Chemistry for AMR Challenge – target-based therapeutics.
- Non-vaccine approaches to prevent neonatal sepsis
- Diagnostics for neonatal sepsis
- NIAID’s 2027 Broad Agency Announcement (BAA, HHS-NIH-NIAID-BAA2026-1) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases. NIAID estimates up to $16 million for the award of up to 4 cost reimbursement completion type contracts. For the fungal community, research area 002 applies: Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales. Proposals are due by 8 Dec 2026. Go here for the announcement; see also the 17 Oct 2026 newsletter (“NIAID/DMID’s 2027 BAA calls for antibacterial and antifungal therapeutics”) for further commentary.
- OHAMR (European Partnership on One Health AMR) have announced the 2nd call in their plan to fund €253 million of AMR research over 10 years. The call is constructed around the theme of “Transmission,” it opened on 18 Nov 2026, its home webpage is here, and pre-proposals are due 1 Feb 2027. See the 8 Nov 2026 newsletter for additional commentary.
- The India AMR Co-Development Programme (I-AMR-CDP) is a collaboration between Venus Remedies Limited, the Indian Government, GARDP, ADVANCE-ID, and Singapore’s Experimental Drug Development Centre that seeks to support antibacterial R&D based in India. The website that is open for applications until 31 Dec 2026; you might want to also review this LinkedIn post.
- ENABLE-2 has continuously open calls for both its Hit-to-Lead program as well as its Hit Identification/Validation incubator. Applicants must be academics and non-profits in Europe due to restrictions from the funders. Applications are evaluated in cycles … see the website for details on current timing for reviews.
- BARDA’s long-running BAA (Broad Agency Announcement) for medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases is now BAA-23-100-SOL-00004 and offers support for both antibacterial and antifungal agents (as well as antivirals, antitoxins, diagnostics, and more). Note especially these Areas of Interest: Area 3.1 (MDR Bacteria and Biothreat Pathogens), Area 3.2 (MDR Fungal Infections), and Area 7.2 (Antibiotic Resistance Diagnostics for Priority Bacterial Pathogens). Although prior BAAs used a rolling cycle of 4 deadlines/year, the updated BAA released 26 Sep 2023 has a 5-year application period that ends 25 Sep 2028 and is open to applicants regardless of location: BARDA seeks the best science from anywhere in the world! See also this newsletter for further comments on the BAA and its areas of interest.
- HERA Invest was launched August 2023 with €100 million to support innovative EU-based SMEs in the early and late phases of clinical trials. Part of the InvestEU program supporting sustainable investment, innovation, and job creation in Europe, HERA Invest is open for application to companies developing medical countermeasures that address one of the following cross-border health threats: (i) Pathogens with pandemic or epidemic potential, (ii) Chemical, biological, radiological and nuclear (CBRN) threats originating from accidental or deliberate release, and (iii) Antimicrobial resistance (AMR). Non-dilutive venture loans covering up to 50% of investment costs are available. A closing date is not posted insofar as I can see — applications are accepted on a rolling basis; go here for more details.
- The AMR Action Fund is open on an ongoing basis to proposals for funding of Phase 2 / Phase 3 antibacterial therapeutics. Per its charter, the fund prioritizes investment in treatments that address a pathogen prioritized by the WHO, the CDC and/or other public health entities that: (i) are novel (e.g., absence of known cross-resistance, novel targets, new chemical classes, or new mechanisms of action); and/or (ii) have significant differentiated clinical utility (e.g., differentiated innovation that provides clinical value versus standard of care to prescribers and patients, such as safety/tolerability, oral formulation, different spectrum of activity); and (iii) reduce patient mortality. It is also expected that such agents would have the potential to strongly address the likely requirements for delinked Pull incentives such as the UK (NHS England) subscription pilot and the PASTEUR Act in the US. Submit queries to contact@amractionfund.com.
- INCATE (Incubator for Antibacterial Therapies in Europe) is an early-stage funding vehicle supporting innovation vs. drug-resistant bacterial infections. The fund provides advice, community, and non-dilutive funding (€10k in Stage I and up to €250k in Stage II) to support early-stage ventures in creating the evidence and building the team needed to get next-level funding. Details and contacts on their website (https://www.incate.net/).
- These things aren’t sources of funds but would help you develop funding applications
- The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D. See also the 7 Feb 2026 newsletter (“The global funding pipeline, 2017-2023: A review”) about an excellent deep dive by the Hub team into patterns of funding over time.
- Antimicrobial Resistance Research and Innovation in Australia is an actively updated summary that covers Australia’s AMR research and patent landscape. It is provided via collaboration between The Lens (an ambitious project seeking to discover, analyse, and map global innovation knowledge) and CSIRO (Commonwealth Scientific and Industrial Research Organisation, an Australian Government agency responsible for scientific research). Lots to explore here!
- Diagnostic developers would find valuable guidance in this 6-part series on in vitro diagnostic (IVD) development. Sponsored by CARB-X, C-CAMP, and FIND, it pulls together real-life insights into a succinct set of tutorials.
- In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).
Last Updated on November 18, 2026 by John Rex